81 results about "Glycoconjugate" patented technology

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

The present disclosure provides methods, compositions, and kits for the rapid release, labeling, and detection of O-glycans present on a glycoconjugate, such as a glycoprotein, glycopeptide, peptidoglycan, or proteoglycan of interest. The compositions and methods allow the released O-glycans to be subjected to high-throughput analysis.

The disclosure discloses a chemical synthesis method and an application of V. cholerae serotype O100 O-antigen oligosaccharides, belonging to the field of chemical technologies. The disclosure uses three monosaccharide building blocks and five carboxylic acid derivatives to synthesize five oligosaccharide fragments of V. cholerae serotype O100 O-antigen under the action of the solvent effect, temperature effect, neighboring group participation effect, etc., through orthogonal protection, selective assembly and amide coupling. The absolute configurations and immunological effects of 3,5-dihydroxyhexanoyl in the O-antigen trisaccharide are illustrated by the synthesized oligosaccharide fragments in combination with the NMR analysis and glycan microarray technology, thereby providing a theoretical basis for further structure-activity study and minimal antigenic epitope screening. The disclosure has excellent application prospects in the aspects of development of V. cholerae synthetic glycoconjugate vaccines and new drugs, etc.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

The present invention relates to a large scale GMP synthesis method of a modified glucan conjugate, and more particularly, to a glucan-guanidine-bisphosphonate conjugate wherein the bisphosphonate is an alendronate group. The large-scale GMP synthesis method related to the invention can be used for producing the glucan-guanidine-bisphosphonate conjugate with high purity and medicinal grade. The invention also relates to an application of the glucan-guanidine-bisphosphonate conjugate in a medicine for treating tumors.

The application relates to the field of food preservation, in particular to a natural bacteriostatic material and a preparation method and application thereof, and a preparation method of the natural bacteriostatic material, which comprises the following steps: mixing natural gelatin and dextran with deionized water, stirring, and freeze-drying to obtain a gelatin-dextran mixture powder, wherein the mass ratio of the natural gelatin to the dextran is 1-2:1-4, and the molecular weight of the dextran is 150-200 kDa; performing a glycosylation reaction on the gelatin-dextran mixture powder to obtain a gelatin-dextran conjugate; dissolving the gelatin-dextran conjugate in a buffer solution to obtain an emulsifier; and homogenizing edible essential oil, the emulsifier and deionized water, and performing ultrasonic emulsification to obtain the natural bacteriostatic material. The preparation method is simple, the conditions are simple, the prepared natural bacteriostatic material has good stability, and the shelf life of food can be prolonged.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

The present invention belongs to the field of composite materials technology, specifically relating to an edible mycorrhizal glycoconjugate-graphene conductive film and its preparation method. This invention uses chitosan-glucan complex (CGC), a root glycoconjugate extracted from the mycorrhizae of Flammulina velutipes, as raw material. Extracting CGC from the mycorrhizae requires only mild acid and alkali treatment to remove components such as proteins, minerals, and lipids, while also minimizing damage to the CGC and improving its purity. The prepared CGC, when used as a dispersant, improves graphene agglomeration. Compared to graphene without CGC, at the optimal concentration of CGC added, the median particle size decreased by 43.11%, and the absolute value of the zeta potential increased by 160.07%. The addition of CGC to graphene significantly enhances its dispersibility, improving the tensile strength and conductivity of the CGC-graphene film.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

A method of making a chitosan conjugate, the method comprising: contacting chitosan, a dicarboxylic acid, and 4-(4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in an aqueous solvent, thereby forming a reaction mixture comprising a chitosan conjugate wherein the chitosan conjugate comprises a repeating unit of formula I, or a conjugate salt thereof, wherein R1 is-(C = O) (CH2) mCO2H; and m is an integer selected from 1 to 12.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

Among its various embodiments, the disclosure provides improved methods for producing glycoconjugates of carrier protein, including CRM197, and bacterial capsular saccharide, including those isolated from various Streptococcus pneumoniae serotypes.

The present invention relates to analytical methods for identifying and quantifying complex glycoconjugate compositions, and in particular to the analysis of polysaccharide components of glycoproteins in a sample. The present invention further relates to the use of liquid chromatography-mass spectrometry systems ("LC-MS systems") in such analytical methods, for example, for process control during glycoconjugate production.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.

FIELD: biotechnology.SUBSTANCE: composition for protecting or treating a human susceptible to pneumococcal infection is described, comprising: (i) at least 21 different glycoconjugates; (ii) a succinate buffer having a pH in the range of 5.0 to 7.5; (iii) sodium chloride; (iv) sodium phosphate; (iv) a surfactant; and (v) an adjuvant.EFFECT: vaccine formulation that facilitates resuspension of the vaccine for administration.71 cl, 7 dwg, 3 tbl, 6 ex

This invention discloses the preparation and application of a base-sensitive linker arm for solid-phase synthesis of polysaccharides, belonging to the fields of glycochemistry and solid-phase synthesis technology. This invention provides a base-sensitive linker arm system comprising an ester core, a linker, and a solid-phase support; one end of the ester core is connected to the solid-phase support, and the other end is connected to the linker; one end of the linker is connected to the ester core, and the other end contains exposed hydroxyl groups; the linker arm system of this invention uses phthalates or alkyl esters as the base-sensitive core structure, which can be cleaved under sodium methoxide conditions, and after hydrogenation deprotection, retains free anomeric sites at the ends of the polysaccharides, or provides amino and carboxyl groups for subsequent preparation of glycoconjugates and glycochips. During the cleavage of the linker arm, the ester protecting groups of the polysaccharide can be removed simultaneously, simplifying the deprotection step and improving efficiency and yield.

This invention belongs to the field of novel glycoconjugates and provides a method for preparing a sialic acid-gold nanomaterial composite. The method includes the following steps: S1: synthesizing a sialic acid ligand functional molecule; S2: synthesizing a PC molecule; S3: replacing the stabilizing molecule on the surface of the gold nanomaterial with a modified molecule under the action of a promoter to obtain a surface-modified material intermediate; S4: activating the surface carboxyl groups of the surface-modified material intermediate, reacting it with the PC molecule and the sialic acid ligand functional molecule, and connecting them through amide bonds. This invention provides a method for creating a sialic acid-gold nanocomposite material with a novel surface structure. The sialic acid molecule is obtained by modifying the structure of natural sialic acid molecules and can specifically recognize and bind to the SARS-CoV-2 S protein. The superhydrophilic properties of the PC group are utilized to reduce non-specific interference of complex environments on the material, while maintaining the biological effects of the sialic acid-gold nanocomposite material.

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

A method for enhancing the immunogenicity of a protein / peptide antigen is provided, wherein the protein / peptide antigen forms a fusion protein with an Fc fragment, preferably with receptor-binding / complement-binding enhanced Fc fragment, and further forms a fusion protein glycoconjugate with a glycosyl group. In the preferred embodiment, the Fc fragment, due to alterations in its amino acid sequence and / or glycosylation, has an enhanced binding capacity to Fc receptors and / or complement protein C1q compared to its native form. Such vaccines can maintain long-term humoral and cellular immune responses, exhibiting higher cellular immune responses and producing higher titers of neutralizing antibodies in immunized animals. Using the SARS-CoV-2 RBD region as the antigen in an immunizing composition, it is formed into a fusion protein with an Fc region that has undergone amino acid sequence and fucose alteration, and further forms a fusion protein glycoconjugate with pneumococcal polysaccharide, for the prevention of SARS-CoV-2 infection-related diseases.

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.

Disclosed in the present invention are a temperature-sensitive material and a glycoconjugate, and a synthesis method therefor and the use thereof in solid-phase glycosynthesis, wherein the temperature-sensitive material is an alkynylated 2-ethyl-2-oxazoline polymer, the azido sugar has a structure of Suger-N-C3N3, and the temperature-sensitive material and the azido sugar are conjugated to form the temperature-sensitive glycoconjugate, thereby realizing the use in solid-phase glycosynthesis. In the present invention, in an actual application stage, the precipitation of glycoconjugate in an aqueous phase can be realized by means of increasing the temperature, the dissolution of a glycoconjugate can be realized by means of reducing the temperature, and the separation of the sugar from the material can also be realized by means of trifluoroacetic acid (TFA). On the basis of the above characteristics, the temperature-sensitive material and the glycoconjugate thereof of the present invention can efficiently and conveniently solve the defects of a sugar intermediate being difficult to separate and purify during polymerization and the steps being uncontrollable, thereby realizing controllable synthesis and purification of sugar, and is of great significance to the research of sugar science.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising such immunogenic compositions and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not present and / or in. The invention also relates to vaccination of human individuals, especially infants and elderly people, against Streptococcus pneumoniae infection using such novel immunogenic compositions.

The present disclosure discloses a specific saccharide fragment for development of Vibrio cholerae vaccines, and belongs to the field of medicine. In the present disclosure, a saccharide fragment related to a trisaccharide of V. cholerae O100 serotype O-antigen is chemically synthesized. Combined with a glycan microarray technology, the structure-activity relationship between different saccharide fragments and antigenicity thereof is evaluated at a molecular level. Glycan microarray screening indicates that 3-hydroxybutyryl is an essential structural feature of the O-antigen. A non-reducing end disaccharide carrying 3-hydroxybutyryl is a potential minimal antigenic epitope, and the disaccharide has strong binding capacity to antibodies and a simple structure, and may serves as a specific saccharide fragment for vaccine development. A glycoconjugate vaccine designed based on the specific saccharide fragment may solve the challenges of difficulty in culturing pathogenic bacteria and heterogeneity of saccharide antigens in naturally extracted polysaccharide vaccines. The present disclosure has bright application prospects in the development of glycoconjugate V. cholerae vaccine, infection detection, and new drug development.

The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.